Roche acquiring PathAI in billion-dollar deal
Swiss healthcare giant Roche has entered into a definitive merger agreement to acquire the digital pathology specialist PathAI in a transaction valued at up to $1.05 billion. The deal involves a $750 million upfront cash payment and up to $300 million in performance and regulatory milestones. Expected to close in the second half of 2026, the acquisition will fold the…
Roche to acquire SAGA Diagnostics in $595m deal
The world’s largest biotechnology company Roche Holding has signed a definitive agreement to acquire the Swedish precision medicine company SAGA Diagnostics for up to $595m. The transaction, which includes upfront considerations alongside commercial and regulatory milestone payments, is expected to close in Q3 2026 subject to customary regulatory approvals. Upon completion, SAGA Diagnostics will be fully integrated into Foundation Medicine,…
Roche Expands Metabolic Portfolio with US$3.5bn acquisition of 89bio
Swiss multinational pharma and diagnostics giant Roche has signed a definitive agreement to acquire California-based biotech group 89bio in a deal worth up to US$3.5bn, planning to expand in cardiovascular, renal and metabolic diseases while diversifying beyond oncology and immunology. Roche will pay US$2.4bn upfront, and up to US$3.5bn if certain milestones are hit tied to commercial success / annual sales targets.…